8050 M1 L1

.pdf
School
University of Cincinnati, Main Campus **We aren't endorsed by this school
Course
PHDD 8050
Subject
Business
Date
Oct 12, 2023
Pages
13
Uploaded by HighnessRamPerson1915 on coursehero.com
PHDD 8050 Module 1 Lecture 1 Lecture 1A - Background Info Lipinski's Rule of 5 LogP value less than 5 (ideally 1.35-1.8) IC50: lower to 10 Molecular weight: 160-480 g/mol The Package Insert The Drug Development Process (PhRMA 2008) Top global contract research organizations (CROs) based on 2017 revenue (in million U.S. dollars) Leading global contract research organizations based on revenue 2017
Total number of registered clinical studies worldwide since 2000 (as of August 2019)* Success Rate of Each Clinical Phase Some Good News: Uptick in the Rate of Approval of New Drugs
CDER approvals by therapeutic area in 2018. 2018's potential blockbuster approvals Sales forecasts are average, annual, global consensus estimates for candidates that are expected to reach blockbuster status by 2024, as reported in Clarivate Analytics' Cortellis database on January 8. *Drugs with breakthrough therapy designation. Reasons For Attrition
Page1of 13
Uploaded by HighnessRamPerson1915 on coursehero.com